NEBULIZED BUDESONIDE AS ADD-ON TO STANDARD THERAPY IN CHILDREN AGED 5-14 YEARS WITH ACUTE EXACERBATION OF ASTHMA
DOI:
https://doi.org/10.22159/ijcpr.2026v18i2.8083Keywords:
Asthma, Children, Budesonide, Salbutamol, Pram scoreAbstract
Objective: Out of the top 20 chronic conditions for global ranking of disability adjusted life years in children, asthma is one of them and specifically in the mid-childhood ages i. e, 5–14 y it ranks amongst the top 10 diseases, so we planned this study to see the efficacy of nebulized budesonide as add-on to standard therapy in children aged 5-14 y with acute exacerbation of asthma.
Methods: This was a prospective, randomized, open labelled, interventional study conducted in 5-14 y old patients of moderate to severe asthma having acute exacerbation. Thirty children with acute exacerbation of asthma presenting in the Paediatric department at PGIMS, Rohtak were randomized and assessed for efficacy according to PRAM score.
Results: PRAM Score at various follow-up time intervals was recorded in both groups and it was observed that mean±SD of PRAM Score at baseline, at 30 min, at 60 min and at 180 min showed non-significant difference during inter-group comparison. At discharge PRAM score was 0.39±0.50 and 0.32±0.48 in group I and group II respectively.
Conclusion: This study showed that both nebulized budesonide as an add-on and standard therapy in children aged 5-14 y with acute exacerbation of asthma showed significant improvement in respiratory status in terms of relief of respiratory symptoms with good safety profile and greater satisfaction with nebulized.
Downloads
References
1. Urbano FL. Review of the NAEPP 2007 expert panel report (EPR-3) on asthma diagnosis and treatment guidelines. J Manag Care Pharm. 2008;14(1):41-9. doi: 10.18553/jmcp.2008.14.1.41, PMID 18240881.
2. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73. doi: 10.1183/09031936.00202013, PMID 24337046.
3. Global Initiative for Asthma. Global strategy for asthma management and prevention: 2018 update. Bethesda (MD): Global Initiative for Asthma; 2018. Available from: https://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/.
4. Geelhoed GC, MacDonald WB. Oral and inhaled steroids in croup: a randomized placebo-controlled trial. Pediatr Pulmonol. 1995;20(6):355-61. doi: 10.1002/ppul.1950200604, PMID 8649914.
5. Barnes PJ. Inhaled glucocorticoids for asthma. N Engl J Med. 1995;332(13):868-75. doi: 10.1056/NEJM199503303321307, PMID 7870143.
6. Van Merode T, Maas T, Twellaar M, Kester A, Van Schayck CP. Gender-specific differences in the prevention of asthma-like symptoms in high-risk infants. Pediatr Allergy Immunol. 2007 May;18(3):196-200. doi: 10.1111/j.1399-3038.2006.00513.x, PMID 17432998.
7. Ober C, Yao TC. The genetics of asthma and allergic disease: a 21st century perspective. Immunol Rev. 2011 Jul;242(1):10-30. doi: 10.1111/j.1600-065X.2011.01029.x, PMID 21682736.
8. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, Fitz Gerald JM. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008 Jan;31(1):143-78. doi: 10.1183/09031936.00138707, PMID 18166595.
9. Global Initiative for Asthma. Global strategy for asthma management and prevention 2015. Bethesda (MD): Global Initiative for Asthma; 2015. Available from: http://www.ginasthma.org/local/uploads/files/GINA_Report_2015_May19.pdf.
10. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, editors. Diseases of the respiratory system. In: Harrison's Principles of Internal Medicine. 20th ed. New York (NY): McGraw-Hill Education; 2018.
11. Pulmonary pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 12th ed. New York (NY): McGraw-Hill; 2011. p. 1031–66.
12. Lee MY, Tsai YG, Chen CJ, Kuen Der Yang D, Chu DM, Cheng SN. Comparative efficacy of nebulized budesonide to intravenous betamethasone treatment for acute childhood asthma. J Med Sci. 2004;24(2):85-9.
13. Global Initiative for Asthma. Global strategy for asthma management and prevention 2015. Bethesda (MD): Global Initiative for Asthma; 2015. Available from: http://www.ginasthma.org/local/uploads/files/gina_report_2015_may19.pdf.
14. Tattersfield AE, Knox AJ, Britton JR, Hall IP. Asthma. Lancet. 2002 Oct 26;360(9342):1313-22. doi: 10.1016/S0140-6736(02)11312-2, PMID 12414223.
15. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. 2007 Jul 18;2007(3):CD000195. doi: 10.1002/14651858.CD000195.pub2, PMID 17636617.
16. Singhi S, Banerjee S, Nanjundaswamy H. Inhaled budesonide in acute asthma. J Paediatr Child Health. 1999 Oct;35(5):483-7. doi: 10.1046/j.1440-1754.1999.355408.x, PMID 10571764.
17. Geelhoed GC, Landau LI, Le Souef PN. Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma. Ann Emerg Med. 1994;23(6):1236-41. doi: 10.1016/S0196-0644(94)70347-7, PMID 8198296.
18. Alangari AA. Corticosteroids in the treatment of acute asthma. Ann Thorac Med. 2014;9(4):187-92. doi: 10.4103/1817-1737.140120, PMID 25276236.
19. Devidayal SS, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr. 1999;88(8):835-40. doi: 10.1080/08035259950168748, PMID 10503681.
20. Asher I, Pearce N. Global burden of asthma among children. Int J Tuberc Lung Dis. 2014;18(11):1269-78. doi: 10.5588/ijtld.14.0170, PMID 25299857.
Published
How to Cite
Issue
Section
Copyright (c) 2026 Dr. Arvind Narwat
This work is licensed under a Creative Commons Attribution 4.0 International License.